Novozymes starts commercial supply of Hyasis from China

Published: 9-May-2012
Ingredients

Sets new standards of safety, consistency and performance for hyaluronic acid


Novozymes Biopharma has supplied the first batches of its Bacillus-derived hyaluronic acid from its newly inaugurated DKK 350m (€47m; US$61m) manufacturing facility in Tianjin, China.

The first commercial products using Hyasis as a raw material should reach the market in Q2.

Thomas Videbæk, executive vice president of Novozymes A/S, in Denmark, said the delivery ‘marks an important milestone on our journey to becoming a leading producer of high quality hyaluronic acid.’

‘With our new patented process, based on the safe bacteria Bacillus subtilis, the market will have access to a new improved source of HA, which is fully compliant with the highest pharmaceutical standards and developed with customers’ specific needs in mind,’ he said.

Videbæk says the market for pharmaceutical use of hyaluronic acid is estimated to be worth DKK1bn.

Novozymes says Hyasis hyaluronic acid offers a number of advantages over competitive sources, including superior heat stability, which permits autoclaving without significant loss of product viscosity, and tight control of molecular weight during production, which allows for excellent control in formulations.

Hyasis also offers ‘unmatched batch-to-batch consistency in production at large-scale’, and the product’s ability to dissolve five times faster than other sources can reduce processing times by up to 50%.

‘We believe we have a very strong offering for the medical device and pharmaceutical markets. Not only is Hyasis manufactured in accordance with requirements for an active pharmaceutical ingredient, it also offers unrivalled safety, consistency and performance to the benefit of our customers and partners,’ added Videbæk.

The Tianjin facility employs a patented water-based process to manufacture Hyasis to Q7 cGMP standards. Working with raw materials that are already Q7 compliant can help medical device and pharmaceutical drug manufacturers to reduce testing time, minimise documentation requirements, save on manufacturing costs and take products to market faster, the firm said.

  • Companies:
  • Novozymes
See more

You may also like

Ingredients

Novozymes reports a good year in 2014

Read more
Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  4. Lonza At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Our community of around 17,500 skilled employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. <br> <br> By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases.
  5. Europa Biosite acquires life science product and service supplier, AMSBIO Europa Biosite will now be able to expand its presence across the key US market, while also bolstering its offerings in stem cell research, regenerative medicine and biospecimens

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
Ingredients

Good outlook for Novozymes after eventful 2013

Strong increase in sales of products for the manufacture of pharmaceuticals
Ingredients

Novozymes’ agreement with GSK brings payback closer

GSK is seeking approval in Europe for diabetes drug Eperzan
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Safe, consistent and sustainable hyaluronic acid

Hyaluronic acid (HA) is a naturally occurring polysaccharide ubiquitous in nature, which is distributed widely throughout connective, epithelial and neural tissues in the human body. Due to its intrinsic biocompatibility, biodegradability and diverse biological functions, HA is widely used in medical devices and pharmaceutical applications. In response to concerns surrounding the purity of many sources of HA, a <i>Bacillus subtilis</i>-based fermentation process has been developed by Novozymes Biopharma.
Ingredients

Novozymes Biopharma aligns recombinant human albumin portfolio with new brand name

Portfolio will bring together rAlbumin product line with introduction of new brand names Recombumin Alpha and Recombumin Prime
Ingredients

Enzymes cut industrial emissions and resource use

Comprehensive scientific review of existing studies shows enzyme technology is a promising means of moving towards cleaner industrial production
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Let enzymes do the work

The use of enzyme catalysts has had a real impact on the synthesis of pharmaceutical ingredients, making it possible to improve some syntheses dramatically and even make some molecules that would otherwise be either impossible or impractical to synthesise. The use of flow reactors in biocatalysis faces challenges arising from the heterogeneous slurry nature of the reaction mixture and problems with gas and liquid handling. But research is being carried out into continuous manufacturing methods for biocatalytic reactions.
Subscribe now